DJ Sartorius Stedim Biotech SA: Information on Document Availability
Sartorius Stedim Biotech SA Sartorius Stedim Biotech SA: Information on Document Availability 21-Jul-2022 / 08:21 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
-----------------------------------------------------------------------------------------------------------------------
Aubagne, July 21, 2022 Information on Document Availability
The report on the first half 2022 results of Sartorius Stedim Biotech Group (Paris: DIM) is now available at:
https://www.sartorius.com/en/company/investor-relations/sartorius-stedim-biotech-sa-investor-relations
It contains the following information: - Business development for the period of January to June 2022 as well as the 2022 full year forecast forthe Sartorius Stedim Biotech Group - Consolidated financial statements for the period ended June 30, 2022
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2021, the company employed more than 10,400 people, and earned sales revenue of around 2.89 billion euros.
Contact
Petra Müller
Head of Investor Relations
+49 (0)551.308.6035
petra.mueller2@sartorius.com
-----------------------------------------------------------------------------------------------------------------------
Regulatory filing PDF file File: Sartorius Stedim Biotech - Rapport financier semestriel de janvier à juin 2022
=----------------------------------------------------------------------------------------------------------------------
Language: English
Company: Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone: +33 44 284 5600
E-mail: info@sartorius-stedim.com
Internet: www.sartorius-stedim.com
ISIN: FR0013154002
Euronext DIM
Ticker:
AMF Category: Half-yearly financial and audit reports/reduced exams / Terms of availability of the half-yearly
financial report
EQS News ID: 1402595
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
1402595 21-Jul-2022 CET/CEST
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1402595&application_name=news
(END) Dow Jones Newswires
July 21, 2022 02:21 ET (06:21 GMT)
